To achieve selective delivery of AE-emitting radionuclides to tumours for cancer treatment, these radionuclides must be attached to targeting ligands such as monoclonal antibodies (mAbs), or peptides that recognise cell surface receptors displayed on cancer cells (Fig. 6). Here, CD177 is linked to cancer.